3 citations
,
April 1977 in “PubMed” In this study, patients with varying severities of acne, seborrhoea, and hirsutism responded differently to Cyproteronacetate and Ethinyloestradiol treatment, with improvement rates dependent on symptom severity and treatment duration.
1 citations
,
April 2022 in “The Journal of Urology” This study observed that discontinuation rates due to side effects were similar for penicillamine and tiopronin among cystinuria patients, and switching to the alternative agent was beneficial for half of those experiencing issues.
13 citations
,
September 2011 in “American Journal of Clinical Dermatology” This review describes the dermatological uses of the contraceptive ethinylestradiol/chlormadinone acetate for conditions linked to high androgen levels and reports no new clinical results.
3 citations
,
July 2012 in “Indian Journal of Psychological Medicine” Olanzapine helped a man who thought he had bugs on his skin.
3 citations
,
April 2021 in “Oncology Times” This study reports that sacituzumab govitecan achieved a 33.3% overall response rate in patients with metastatic triple-negative breast cancer who had prior treatments, with a median response duration of 7.7 months.
July 2023 in “Research Square (Research Square)” In this study, the application of topical cetirizine 1% once daily for four months in Egyptian male patients with androgenetic alopecia led to a significant increase in terminal hairs and improved hair diversity, with promising safety and efficacy outcomes.
1 citations
,
April 2017 in “European Psychiatry” This case study describes a patient who developed mild eosinophilia and a skin rash after starting clozapine, which resolved without discontinuing the medication.
This article reviews numerous drug reactions and interactions for various medications and does not present new research findings.
January 2025 in “American Journal of Translational Research” This study reported that the combination of EE-CPA and raloxifene effectively manages PCOS-related infertility, enhancing pregnancy outcomes through improvements in metabolism, sex hormones, ovarian function, and endometrial receptivity, without significantly increasing adverse effects.
March 2002 in “Reactions Weekly” Some birth control pills increase blood clot risk; use them for specific conditions only.
36 citations
,
June 2020 in “Dermatologic Therapy” This article reviews the use of cyclosporine in dermatological conditions, noting its benefits in treating various skin diseases despite known adverse effects like nephrotoxicity and hypertension, and highlights its preferred use over other immunosuppressants due to an early therapeutic response and a good safety profile.
7 citations
,
March 2025 in “Cytotechnology”
December 2013 in “Nursing2023” The FDA approved a new breast cancer treatment, found flu shots may reduce heart risks, questioned the safety of fast-tracked drug approvals, showed statins don't help with certain pneumonia, and approved a new dementia imaging agent.
May 2024 in “News Digital Object Group” 37 citations
,
September 2002 in “Acta pædiatrica” In this study, a patient with cystic fibrosis developed iatrogenic Cushing's syndrome due to impaired clearance of budesonide from concurrent itraconazole use, highlighting the need for regular monitoring in such combination therapies.
June 2026 in “Journal of Investigative Dermatology” This study reported that the anti-γc antibody hC2 restored hair follicle homeostasis and suppressed hair loss in an AA-like mouse model by inhibiting autoreactive T-cell activity, suggesting that hC2 may offer a safer and more effective treatment for alopecia areata compared to current Jak inhibitors.
May 2025 in “CPT Pharmacometrics & Systems Pharmacology” This study examined the safety profile of ritlecitinib, a drug for alopecia areata, and found that it does not cause significant QTc prolongation or severe lymphopenia, with no unique safety risks expected in adolescents.
5 citations
,
February 2013 in “PubMed” In this case study, an 11-year-old girl with a Cladosporium scalp infection showed significant improvement in hair growth and appearance after treatment with itraconazole.
16 citations
,
April 2014 in “Expert Opinion on Pharmacotherapy” This review discusses the pharmacological profile of teriflunomide for treating relapsing multiple sclerosis, highlighting its safety and effectiveness in reducing relapses and slowing disability progression, though direct comparisons with other oral medications are lacking.
September 2004 in “Inpharma Weekly”
July 2023 in “Journal of Clinical Medicine” In this study, researchers investigated factors predicting resistance to clomiphene citrate in women with anovulatory PCOS, identifying AMH and SHBG levels as significant indicators, but they found no reliable thresholds for predicting resistance to the standard 50 mg/day dose.
13 citations
,
November 2021 in “Pediatric Dermatology” This study found that oral tofacitinib was effective and well tolerated for treating alopecia areata in most pediatric patients, with nearly 73% experiencing hair regrowth.
2 citations
,
November 2025 in “PLoS ONE” This study found that CDK4/6 inhibitors for HR+/HER2- advanced breast cancer are linked to typical adverse events such as fatigue and neutropenia, while also identifying unexpected reactions, highlighting potential safety concerns in their real-world use.
July 2020 in “Indian journal of sexually transmitted diseases and AIDS” This article highlights the importance of an algorithmic approach to manage multiple opportunistic infections in HIV-infected patients due to the risk of drug interactions and complications, but reports no new clinical results.
88 citations
,
January 2001 in “Dermatology” This study found that the monophasic oral contraceptive ethinylestradiol/chlormadinone acetate was more effective in treating mild to moderate papulopustular acne in women than ethinylestradiol/levonorgestrel.
1 citations
,
April 2019 in “Journal of Investigative Dermatology” This study concluded that the topical gel VB1953 reduced inflammatory and non-inflammatory acne lesions and resistant bacteria in patients with clindamycin-resistant acne, showing promise as an effective treatment.
April 2025 in “Frontiers in Pharmacology” This study found that targeting RARβ and RXRA with CANA, in combination with MPA, could help overcome progestin resistance by restoring BAX levels and downregulating CRABP2, suggesting a novel strategy for improving clinical efficacy in this context.
9 citations
,
March 2008 in “British Journal of Dermatology” This article describes a case of hypertrichosis potentially induced by using efalizumab but provides no new clinical study results.
67 citations
,
February 2022 in “International Journal of Molecular Sciences” This study developed a nanofiber wound dressing combining ciprofloxacin and tetracycline hydrochloride, which demonstrated strong antibacterial activity against E. coli and S. aureus and showed good biocompatibility with human skin fibroblast cells, indicating significant potential for wound healing applications.
January 2024 in “Journal of neurogastroenterology and motility” This study found that gQlab probiotics improved overall IBS symptoms, particularly in female and constipation-predominant patients, compared to placebo after 4 weeks of treatment.